“…A number of WBM site inhibitors have been discovered [ 14 , 19 , 20 , 21 ], but these have yet to progress sufficiently for thorough interrogation in cells or animal models. The discovery of WIN site inhibitors (WINi), in contrast, has been very successful (e.g., [ 1 , 2 , 15 , 16 , 17 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 ]), due in large part to the tractability of the WIN site and a deep understanding of structure–activity relationships in this class of agents.…”